Back to top
more

Hims & Hers Health (HIMS)

(Delayed Data from NYSE)

$22.80 USD

22.80
17,268,814

+2.30 (11.22%)

Updated Oct 15, 2024 04:00 PM ET

After-Market: $22.73 -0.07 (-0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List

The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.

Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $18.73, signifying a -0.11% move from its prior day's close.

Hims & Hers Health (HIMS) Soars 10.1%: Is Further Upside Left in the Stock?

Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Company News for Oct 4, 2024

Companies In the News Are: LEVI, STZ, HIMS, SHEL.

Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $18.95, indicating a -1.86% shift from the previous trading day.

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $16.44, representing a +0.86% change from its previous close.

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $16.28, moving -1.75% from the previous trading session.

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Debanjana Dey headshot

Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?

HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day

Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day

Ethan Feller headshot

Eli Lilly: The Next $1 Trillion Market Cap Stock?

Eli Lilly showcased the exceptional strength of its business during its quarterly earnings meeting on Thursday morning

Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 20% and 3.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?

Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Boston Scientific (BSX) Rides on Global Growth, Buyouts

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Debanjana Dey headshot

Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?

Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.

Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings

Haemonetics' (HAE) first-quarter fiscal 2025 results are likely to reflect the benefits of hemostasis management growth.

Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?

Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can RadNet's (RDNT) Service Fee Revenues Help Lift Q2 Earnings?

RadNet's (RDNT) Imaging Center segment is likely to have gained from the increased reimbursement from commercial and capitated payors and strong procedure volumes in the second quarter of 2024.

Can Hims & Hers Health (HIMS) Run Higher on Rising Earnings Estimates?

Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings

Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.